Riabni Gains Indication to Treat Rheumatoid Arthritis
June 6, 2022Dupixent Approved for Eczema in Young Children
June 7, 2022June 7, 2022 – The U.S. FDA has approved an expanded indication for Sanofi's Lantus® (insulin glargine)to improve glycemic control in adult and pediatric patients who have diabetes mellitus (type 1 or type 2).
- Prior to this expansion, Lantus was indicated to improve glycemic control in adults who had type 1 or type 2 diabetes mellitus, and in pediatric patients who had type 1 diabetes mellitus.
- Lantus dosing is individualized based on the patient's metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use.
- The FDA first approved Lantus in 2000.